Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: Retrospective analysis of 744 cases;Vergleich der risikokalkulation für trisomie 21 nach Nicolaides mit einer neu entwickelten software: Retrospektive analyse an 744 fällen

Geburtshilfe und Frauenheilkunde

Volumn 63, Issue 2, 2003, Pages 148-152

  Scharf, Alexander ^a   Schmidt, P ^b   Seppelt, M ^a   Maul, H ^a   Wustemann M ^a   Sohn, C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Praxis Dr Schmidt   (Germany)

Author keywords

Aneuploidy; Down syndrome; Nuchal translucency; Risk; Software

Indexed keywords

ANEUPLOIDY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN SYNDROME; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MATERNAL AGE; PREGNANCY COMPLICATION; PRENATAL SCREENING; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 0037293329     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37465     Document Type: Article

References (15)

1. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multi-centre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998; 351: 343-346
2. Pandya PP, Snijders RJM, Johnson SJ, Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995; 102: 957-962
3. Schuchter K, Wald N, Hackshaw AK, Hafner E, Liebhart E. The distribution of nuchal translucency at 10-13 weeks of pregnancy. Prenat Diagn 1998; 18: 281-286
4. Krampl E, Wertaschnigg D, Husslein P. Down-Syndrom-Screening im ersten Trimenon. Geburtsh Frauenheilk 2002; 62: 843-848
5. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992; 304: 867-889
6. Snijders RJM, Holzgreve W, Cuckle H, Nicolaides KH. Maternal age-specific risks for trisomies at 9-14 weeks' gestation. Prenat Diagn 1994; 14: 543-552
7. Braithwaite JM, Morris RW, Economides DL. Nuchal translucency measurements: frequency distribution and changes with gestation in a general population. Br J Obstet Gynaecol 1996; 103: 1201-1204
8. Wald N, Stone R, Cuckle HS, Grudzinskas JG, Barkai G, Brambati B, Teisner B, Fuhrmann W. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. Br Med J 1992; 305: 28
9. Kowalcek I, Mühlhoff A, Bieniakiewiz I, Gembruch U. Nicht-invasive und invasive Pränataldiagnostik und psychische Beanspruchung der Schwangeren. Geburtsh Frauenheilk 2001; 61: 593-598
10. Snijders RJM, Nicolaides KH. Assessment of risks. In: Snijders RJM, Nicolaides KH (eds). Ultrasound Markers for Fetal Chromosomal Defects. Carnforth, UK: Parthenon Publishing, 1996: 109-113
11. Palomaki GE, Haddow JE. Maternal serum alpha-fetoprotein, age, and Down syndrome risk. Am J Obstet Gynecol 1987; 156: 460-463
12. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167-170
13. Nicolaides KK, Sebire N, Snijders RJM. Nackentransparenz und Chromosomenanomalien. In: Nicolaides KH (Hrsg). Die Ultraschalluntersuchung in der 11.-14. Schwangerschaftswoche. Diagnostik fetaler Fehlbildungen. Carnforth, UK: Parthenon Publishing Group 1999 (Deutsche Übersetzung 2000): 3-72
14. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346
15. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17: 821-829